Thymosin Alpha-1 Dosage, Protocol, and Reconstitution Guide
Thymosin Alpha-1
Thymosin Alpha-1 (Tα1), also known in synthetic form as thymalfasin, is a 28-amino-acid immunomodulatory peptide studied for its effects on T-cell activity, dendritic-cell function, cytokine signaling, and immune regulation. Unlike many research peptides, Tα1 has been evaluated in multiple human clinical trials across infectious disease, cancer, vaccine-response, and immune-related settings.
How It Works
Immune Signaling Support → T-Cell Function ↑ → Immune Modulation ↑ → Recovery / Resilience Support
Thymosin Alpha-1 influences multiple components of immune regulation, including T-cell and dendritic-cell activity and cytokine signaling. Its effects are generally described as immunomodulatory rather than as direct immune stimulation.
Low-Dose / Gradual Research-Use Protocol
5 mg vial + 1.5 mL BAC Water → 1 unit = 33 mcg → Twice-Weekly Immune Support
Standard Setup
Vial
5 mg
Water
1.5 mL bacteriostatic water
Concentration
3.33 mg/mL
Conversion
1 unit = 33.3 mcg
Weeks 1–2
Starting Dose
Dose500 mcg
Units15 units
Volume0.15 mL
Frequency2x weekly
Weeks 3–4
Build
Dose750 mcg
Units23 units
Volume0.23 mL
Frequency2x weekly
Weeks 5–8
Standard Range
Dose1 mg
Units30 units
Volume0.30 mL
Frequency2x weekly
Why this structure?
The gradual protocol provides a lower-dose research-use framework for comparison. Published human studies, however, more commonly used fixed clinical-study regimens such as 1.6 mg subcutaneously twice weekly.
Research-Use Note: This gradual step-up schedule is not the regimen most commonly used in published human trials. It is included as a lower-dose research-use framework rather than a validated clinical dosing standard.
The gradual protocol provides a lower-dose research-use framework for comparison. Published human studies, however, more commonly used fixed clinical-study regimens such as 1.6 mg subcutaneously twice weekly.
Research-Use Note: This gradual step-up schedule is not the regimen most commonly used in published human trials. It is included as a lower-dose research-use framework rather than a validated clinical dosing standard.
Common Clinical Research Protocol
Higher Clinical-Style Range → More Aggressive Immune Support Context
Higher Range
Dose1–1.6 mg per injection
Frequency2x weekly
Evidence Note: A 1.6 mg subcutaneous dose twice weekly has been used repeatedly in published human clinical studies. Duration varies substantially by indication and study design.
How to Use Thymosin Alpha-1 (Cycle, Timing & Injection)
Frequency2 times weekly
TimingConsistent days each week
Cycle LengthVaries by indication; published studies range from several weeks to many months
Injection TypeSubcutaneous
Common SitesAbdomen, thigh, upper arm
Timing Considerations
Published studies generally define dose and frequency rather than a specific time of day. When using a twice-weekly framework, maintaining consistent dosing days is more relevant than morning versus evening timing..
Where to Inject
Subcutaneous injection is the common route discussed.
Abdomen, thigh, and upper arm are common injection sites.
Rotate injection sites to reduce irritation.
Areas of Clinical Research
Chronic viral infection and immune-response research
Vaccine-response and immune-function studies
Oncology and adjunctive immune-modulation research
Sepsis and critical-illness research
Broader immune-regulation studies
Simple Strategy
Use in Phases
This is an immune-support peptide, so the goal is usually immune resilience and modulation rather than physique change.
Goal-Based Use
Duration Depends on Research Context
Unlike many short-cycle research peptides, Thymosin Alpha-1 has been studied over both short and extended treatment periods. Duration should therefore be described in the context of the specific clinical study rather than as one universal cycle.
Reconstitution & Dosing (5 mg Vial)
Reconstitution & Dosing
Vial5 mg
Water1.5 mL
Concentration3.33 mg/mL
Conversion1 unit = 33 mcg
Dose Reference
15 units = about 500 mcg
23 units = about 750 mcg
30 units = about 1 mg
48 units = about 1.6 mg
Reconstitution Steps
Draw 1.5 mL bacteriostatic water
Inject slowly down vial wall
Gently swirl, do not shake
Refrigerate immediately
Storage & Shelf Life
Storage & Shelf Life
Lyophilized (unmixed)
Refrigerated (2–8°C): ~12–24 months
Frozen (−20°C): up to ~2–3 years
Store sealed, dry, and protected from light
Reconstituted (mixed)
Refrigerated (2–8°C): about 30 days typical use window
Do not freeze after mixing
Avoid repeated temperature changes
Best Practice
Handling
Keep the vial cold, protected from light, and avoid unnecessary handling.
Visual Check
If the solution becomes cloudy, discolored, or contains particles, it is safer not to continue using it.
Research Duration & Reassessment
Defined Research Period → Reassess → Continue or Stop Based on Study Context
Research Duration & Reassessment
Duration
Study-dependent; published protocols range from weeks to months
Time Off
No universal clinically established off-period
Reassessment
Depends on indication, study design, and treatment response
Why duration varies:
Thymosin Alpha-1 has been studied across very different clinical settings, so there is no single standard cycle length or required break between treatment periods. Published protocols have ranged from short treatment courses to several months depending on the research indication.
Thymosin Alpha-1 has been studied across very different clinical settings, so there is no single standard cycle length or required break between treatment periods. Published protocols have ranged from short treatment courses to several months depending on the research indication.
Examples From Published Research
Twice-Weekly Model
1.6 mg SC twice weekly
Used repeatedly in published human clinical studies
Loading Model
More frequent initial dosing → twice weekly
Used in some indication-specific clinical studies
Extended Model
Treatment continued for several months
Studied in some chronic-disease research settings
Important Context
There is no universal clinically established cycle length for Thymosin Alpha-1
A required 2–4 week break between treatment periods has not been established
Dose, frequency, and duration have varied according to the condition being studied
Clinical protocols from a specific disease setting should not automatically be generalized to general immune-support use
Monitoring During Use
General illness frequency or recovery trends
Energy and resilience during stress
Injection site tolerance
Any unusual immune-related symptoms
Studied Effects & Clinical Research
Studied for modulation of T-cell and dendritic-cell activity
Evaluated in human clinical research involving infectious disease, oncology, and immune regulation
Studied as an adjunct in vaccine-response and immune-function research
Human clinical experience is substantially greater than for many commonly discussed research peptides
Safety and efficacy vary by indication and should not be generalized across uses
Potential Side Effects
Injection-site irritation, redness, or discomfort have been reported
Clinical studies have generally reported favorable tolerability, although safety depends on the indication and treatment context
Evidence from studied clinical uses should not automatically be applied to general or unsupervised research use
Long-term safety outside studied clinical settings is less certain
Supportive Context
Immune Research → Adjunctive Clinical Research → Indication-Specific Context
Immune Research: Studied within defined disease and immune-modulation settings
Adjunctive Research: Evaluated alongside vaccines, antivirals, cancer therapies, and other standard treatments
Important: Clinical combinations are indication-specific and should not be interpreted as general-purpose peptide stacking recommendations
Important Notes
Thymosin Alpha-1 has considerably more human clinical research than many commonly discussed research peptides.
A 1.6 mg subcutaneous dose twice weekly has been used repeatedly in published clinical studies, but dosing and duration vary by indication.
Some studies have used an initial period of more frequent dosing before transitioning to twice-weekly administration.
Clinical evidence from a specific disease or treatment setting should not automatically be generalized to general wellness or immune-support use.
Important Disclaimer
Thymosin Alpha-1 is not FDA-approved for general use in the United States, though synthetic thymalfasin has been used clinically in multiple countries. This content is for educational purposes only.
Research & References
Primary Research
- Goldstein AL, Goldstein A. From Lab to Bedside: Emerging Clinical Applications of Thymosin Alpha 1. Expert Opinion on Biological Therapy. 2009.
- Garaci E, Favalli C, Pica F, et al. Thymosin Alpha 1: From Bench to Bedside. Annals of the New York Academy of Sciences. 2007.
- Sherman KE. Thymosin Alpha 1 for Treatment of Hepatitis C Virus: Promise and Proof. Annals of the New York Academy of Sciences. 2010.
- Wu J, Zhou L, Liu J, et al. The Efficacy of Thymosin Alpha 1 for Severe Sepsis (ETASS): A Multicenter, Single-Blind, Randomized and Controlled Trial. Critical Care. 2013.
- King RS, Tuthill C. Evaluation of Thymosin Alpha 1 in Nonclinical Models of the Immune-Suppressing Indications Melanoma and Sepsis. Expert Opinion on Biological Therapy. 2015.
Research Note: Thymosin Alpha-1 (Thymalfasin) has one of the largest human clinical evidence bases among research peptides, with published trials in hepatitis B and C, sepsis, and immune deficiency. It is approved in over 35 countries for select indications but remains unapproved by the FDA for general use in the United States.
Comments
Post a Comment